Saeed Sadeghi

3.9k total citations · 1 hit paper
42 papers, 1.7k citations indexed

About

Saeed Sadeghi is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Saeed Sadeghi has authored 42 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 17 papers in Surgery and 13 papers in Molecular Biology. Recurrent topics in Saeed Sadeghi's work include Cholangiocarcinoma and Gallbladder Cancer Studies (16 papers), Fibroblast Growth Factor Research (10 papers) and Cancer Genomics and Diagnostics (8 papers). Saeed Sadeghi is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (16 papers), Fibroblast Growth Factor Research (10 papers) and Cancer Genomics and Diagnostics (8 papers). Saeed Sadeghi collaborates with scholars based in United States, Spain and Belgium. Saeed Sadeghi's co-authors include Michael F. Press, Lisa O’Rourke, J. Maltzman, Véronique Dièras, Alexey Manikhas, Mark D. Pegram, Xavier Pivot, Cristina Oliva, Gilles Romieu and Esther M. John and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Saeed Sadeghi

39 papers receiving 1.6k citations

Hit Papers

Lapatinib Combined With Letrozole Versus Letrozole and Pl... 2009 2026 2014 2020 2009 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
    2009 766 citations Stephen Johnston, John Pippen et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Saeed Sadeghi United States 17 1.1k 513 444 366 289 42 1.7k
Débora De Melo Gagliato Brazil 14 953 0.8× 528 1.0× 501 1.1× 426 1.2× 170 0.6× 36 1.5k
Akihiko Osaki Japan 23 747 0.7× 283 0.6× 528 1.2× 529 1.4× 153 0.5× 116 1.7k
Ernesto Wasserman United States 17 812 0.7× 358 0.7× 377 0.8× 418 1.1× 141 0.5× 35 1.2k
Ki Y. Chung United States 20 1.6k 1.4× 702 1.4× 208 0.5× 617 1.7× 267 0.9× 62 2.4k
Allyson J. Ocean United States 18 1.1k 1.0× 496 1.0× 205 0.5× 477 1.3× 252 0.9× 81 1.9k
Holger W. Hirte Canada 20 978 0.9× 430 0.8× 305 0.7× 763 2.1× 216 0.7× 46 2.0k
Daniela Kandioler Austria 23 835 0.7× 350 0.7× 529 1.2× 622 1.7× 351 1.2× 55 1.7k
Peter J. Hosein United States 21 1.6k 1.5× 659 1.3× 560 1.3× 287 0.8× 454 1.6× 111 2.4k
Giovanna Masci Italy 21 789 0.7× 376 0.7× 526 1.2× 471 1.3× 121 0.4× 73 1.6k

Countries citing papers authored by Saeed Sadeghi

Since Specialization
Citations

This map shows the geographic impact of Saeed Sadeghi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Saeed Sadeghi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Saeed Sadeghi more than expected).

Fields of papers citing papers by Saeed Sadeghi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Saeed Sadeghi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Saeed Sadeghi. The network helps show where Saeed Sadeghi may publish in the future.

Co-authorship network of co-authors of Saeed Sadeghi

This figure shows the co-authorship network connecting the top 25 collaborators of Saeed Sadeghi. A scholar is included among the top collaborators of Saeed Sadeghi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Saeed Sadeghi. Saeed Sadeghi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hu, Ran, Benjamin V. Tran, Shuo Li, et al.. (2025). Noninvasive prognostication of hepatocellular carcinoma based on cell-free DNA methylation. PLoS ONE. 20(4). e0321736–e0321736.
2.
Sadeghi, Saeed, et al.. (2024). Copper-oxide nanoparticles effects on goldfish (Carassius auratus): Lethal toxicity, haematological, and biochemical effects. Veterinary Research Communications. 48(3). 1611–1620. 20 indexed citations
3.
4.
Sadeghi, Saeed. (2022). Infigratinib for cholangiocarcinoma. Drugs of today. 58(7). 327–334. 7 indexed citations
5.
Savjani, Ricky R., et al.. (2022). Radiation Therapy for Mantle Cell Lymphoma with Orbital Involvement. Radiology Imaging Cancer. 4(4). e220027–e220027. 1 indexed citations
6.
Abou‐Alfa, Ghassan K., Ivan Borbath, Allen Lee Cohn, et al.. (2020). 1014TiP PROOF: A multicenter, open-label, randomized, phase III trial of infigratinib vs gemcitabine + cisplatin in patients with advanced cholangiocarcinoma with FGFR2 gene rearrangements. Annals of Oncology. 31. S701–S702. 1 indexed citations
7.
Court, Colin M., Shuang Hou, Lian Liu, et al.. (2020). Somatic copy number profiling from hepatocellular carcinoma circulating tumor cells. npj Precision Oncology. 4(1). 16–16. 12 indexed citations
8.
Javle, Milind, Saeed Sadeghi, Sameek Roychowdhury, et al.. (2020). SO-5 Efficacy of second-line chemotherapy in patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions: A retrospective analysis. Annals of Oncology. 31. S219–S219. 2 indexed citations
9.
Abou‐Alfa, Ghassan K., Ivan Borbath, Lipika Goyal, et al.. (2020). P-144 Infigratinib versus gemcitabine plus cisplatin as first-line therapy in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: phase 3 PROOF trial. Annals of Oncology. 31. S136–S137. 2 indexed citations
10.
Makawita, Shalini, Ghassan K. Abou‐Alfa, Sameek Roychowdhury, et al.. (2020). Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial. Future Oncology. 16(30). 2375–2384. 72 indexed citations
11.
Sadeghi, Saeed, et al.. (2019). Systemic Therapy for Primary Liver Tumors. Surgical Oncology Clinics of North America. 28(4). 695–715. 7 indexed citations
12.
Winograd, Paul, Shuang Hou, Colin M. Court, et al.. (2018). Evaluation of hepatocellular carcinoma circulating tumor cells expressing programmed death-ligand 1. HPB. 20. S2–S3. 9 indexed citations
13.
Javle, Milind, Robin Kate Kelley, Sameek Roychowdhury, et al.. (2018). Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions. Annals of Oncology. 29. viii720–viii720. 33 indexed citations
14.
Mackey, John R., Tadeusz Pieńkowski, John Crown, et al.. (2016). Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. Annals of Oncology. 27(6). 1041–1047. 48 indexed citations
15.
Shin, Daniel Sanghoon, et al.. (2014). Metastatic human epidermal growth factor 2 (HER2/neu) amplified breast cancer with acute fulminant hepatitis responding to trastuzumab, pertuzumab and carboplatin. BMJ Case Reports. 2014. bcr2013203400–bcr2013203400. 3 indexed citations
16.
Hurvitz, Sara A., et al.. (2014). Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine. Pharmacogenomics and Personalized Medicine. 7. 329–329. 16 indexed citations
17.
18.
Johnston, Stephen, John Pippen, Xavier Pivot, et al.. (2009). Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer. Journal of Clinical Oncology. 27(33). 5538–5546. 766 indexed citations breakdown →
19.
Sadeghi, Saeed, Victor J. Marder, Daphne Stewart, et al.. (2003). Safety of plasmin in the setting of concomitant aspirin and heparin administration in an animal model of bleeding. Journal of Thrombosis and Haemostasis. 1(12). 2621–2625. 7 indexed citations
20.
Levine, Alexandra M., Saeed Sadeghi, Byron M. Espina, Anil Tulpule, & Bharat N. Nathwani. (2002). Characteristics of indolent non‐hodgkin lymphoma in patients with type 1 human immunodeficiency virus infection. Cancer. 94(5). 1500–1506. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Débora De Melo Gagliato Breakdown of academic impact, for papers by Akihiko Osaki Breakdown of academic impact, for papers by Ernesto Wasserman Breakdown of academic impact, for papers by Ki Y. Chung Breakdown of academic impact, for papers by Allyson J. Ocean Breakdown of academic impact, for papers by Holger W. Hirte Breakdown of academic impact, for papers by Daniela Kandioler Breakdown of academic impact, for papers by Peter J. Hosein Breakdown of academic impact, for papers by Giovanna Masci
Rankless by CCL
2026